Skip to main content

Table 1 Baseline characteristics

From: Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series

Variable Overall (n = 15) Initial therapy (n = 7) Second-line therapy (n = 8) P value
Age (years) 62 (45–67) 52 (39–62) 64 (57–67) 0.12
Female 8 (53) 5 (71) 3 (38) 0.32
Systolic BP (mmHg) 140 (124–148) 124 (114–140) 147 (135–164) 0.037
Diastolic BP (mmHg) 82 (72–86) 80 (67–86) 83 (79–89) 0.29
Serum Creatinine (mg/dL) 1.2 (0.8–1.5) 0.8 (0.5–0.9) 1.3 (1.2–2.1) 0.011
eGFR (ml/min/1.73 m2) 65 (40–100) 100 (62–123) 56 (29–66) 0.024
eGFR Group     0.45
  > 60 ml/min/1.73 m2 10 (67) 6 (86) 4 (50)  
 30–60 ml/min/1.73 m2 3 (20) 1 (14) 2 (25)  
  < 30 ml/min/1.73 m2 2 (13) 0 (0) 2 (25)  
UPCR (g/g) 8.2 (6.8–11.4) 6.9 (5.2–10.2) 10.1 (8.0–11.7) 0.15
UPCR group     0.41
  < 4a 1 (7) 1 (14) 0 (0)  
 4–8 5 (33) 3 (43) 2 (25)  
  > 8 9 (60) 3 (43) 6 (75)  
Nephrotic Syndromeb 13 (87) 7 (100) 6 (75) 0.47
Albumin (g/dL) 2.7 (2.5–2.8) 2.7 (2.5–2.8) 2.6 (2.4–3.1) 0.86
Total Cholesterol (mg/dL)c 350 (252–371) 341 (252–367) 371 (249–438) 0.34
Triglycerides (mg/dL)c 172 (122–270) 134 (77–192) 177 (155–546) 0.14
Time Since Biopsy Diagnosis (months) 9 (3–24) 3 (0.5–4) 23 (16–60) 0.011
On ACE-I or ARB 13 (87) 5 (71) 8 (100) 0.20
On Statin 8 (53) 2 (29) 6 (75) 0.13
Treatment Indications     
 Failure of ACE-I or ARBd 8 (53) 2 (29) 6 (75) 0.13
 Declining Renal Function 5 (33) 1 (14) 4 (50) 0.30
 Debilitating Symptoms from nephrotic syndrome 10 (67) 5 (71) 5 (63) 0.99
 Relapsing Disease 6 (38) NA 6 (75) NA
 Refractory Disease 3 (19) NA 3 (38) NA
  1. Data are presented as median (interquartile range) and n (%)
  2. Abbreviations: ACE-I angiotensin converting enzyme, ARB angiotensin receptor blocker, BP blood pressure, eGFR estimated glomerular filtration rate, UPCR urinary protein: creatinine ratio
  3. aThe patient with a UPCR < 4 g/g had decompensated nephrotic syndrome with refractory edema and an albumin nadir of 1.1 g/dL
  4. bNephrotic syndrome was defined as urinary protein: creatinine ratio > 3.5 g/g, serum albumin < 3 g/dL, and peripheral edema
  5. cOne patient in the second-line therapy group did not have baseline cholesterol or triglycerides
  6. dFailure of ACE-I or ARB was defined as a persistent UPCR > 4 g/g despite at least 6 months of therapy